Table 2. 출생 후 6개월 동안 프로바이오틱스와 갈락토올리고당을 섭취한 영아~2세 나이의 알러지질환 발생율 및 아토피성 습진 변화

	Probiotic		Placebo		Unadjusted		Adjusted*
	n	%	n	%	OR(95% CI)	p value†	OR(95% CI)	p value†
Primary outcome
Allergic disease‡	145/461	31.5	163/464	35.1	0.85(0.64－1.12)	.236	0.82(0.61－1.08)	.159
IgE-associated allergic diseases§	64/456	14.	87/463	18.8	0.71(0.50－1.00)	.052	0.65(0.45－0.94)	.022
Secondary outcome
Eczema	120/461	26.0	15/464	32.3	0.74(0.55－0.98)	.035	0.69(0.52－0.93)	.015
Atopic exzema║	57/459	12.4	82/463	17.7	0.66(0.46－0.95)	.025	0.61(0.42－0.90)	.012
Sensitization¶	127/454	28.0	144/462	31.2	0.86(0.65－1.14)	.289	0.82(0.61－1.10)	.0184

Values in boldface are statistically significant.
Adjusted by means of multivariable losistic regression for sex, delivery by means of cesarean section, breast-feeding for at least 6 months, use of antibitics during the intervention, and regular (daily or ≥2 days a week) use of probitics after the interventions.
The p value was calculated by using logistic regression analysis.
Food allergy, eczema, asthma, or allergic rhinitis.
Food allergy, eczema, asthma, or allergic rhinitis in infants with positive skin prick test responses or antigen-specific IgE levels of greater than 0.7 kU/L.
Eczema in infants with positive skin prick test responses or serum antigen-specific Ig E levels of greater than 0.7 kU/L.
Positive skin prick test response or serum antigen IgE level of greater than 0.7 kU/L.